This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.
In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.
For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.
Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.
Novo Holdings A/S filed an amendment reporting its ownership in MapLight Therapeutics, Inc. It beneficially owns 2,086,622 shares of voting common stock, representing 4.9% of MapLight’s outstanding common shares, based on 42,618,165 shares outstanding as of May 7, 2026.
On July 30, 2026, Novo Holdings sold MapLight shares in open market transactions, including 1,314,195 shares at $12.00 per share and additional blocks at weighted-average prices of $14.19 and $14.69. As of that date, the reporting persons ceased to be beneficial owners of more than five percent of MapLight’s common stock.
MPLT filed a notice for the potential sale of its voting common stock. The filing lists 1,600,000 shares with an associated amount of $24,032,000, tied to trading on the Nasdaq Global Select market. Another figure of 45,345,676 shares is disclosed in the same securities table. The shares proposed for sale were acquired by direct investments for cash on October 20, 2023 (727,533 shares), March 27, 2024 (831,466 shares), and July 18, 2025 (41,001 shares).
Catalyst4, Inc., reported as a 10% owner of MapLight Therapeutics, Inc., purchased a total of 1,209,225 shares of Voting Common Stock in open market or private transactions from July 28–30, 2026. The purchases included 1,000,000 shares at $13.0000 per share and additional shares at $12.6300 and weighted-average prices within ranges of $10.295–$11.28 and $11.31–$12.00 per share. The shares are held of record by Catalyst4, whose board members share voting and dispositive power and each disclaims beneficial ownership; the trades were not marked as made under a Rule 10b5-1 trading plan.
MapLight Therapeutics, Inc. director Troy Cox, through a revocable trust, purchased 15,620 shares of Voting Common Stock on July 28, 2026 at a weighted-average price of $9.5200 per share, with individual trade prices ranging from $9.305 to $9.78.
After this purchase, the trust holds 15,620 shares, and Cox also directly owns 7,864 shares of MapLight Therapeutics Voting Common Stock.
MapLight Therapeutics reported positive topline results from the Phase 2 ZEPHYR trial of ML-007C-MA in adults hospitalized with an acute exacerbation of schizophrenia. The 210/3 mg twice-daily dose met the primary endpoint, producing a statistically significant and clinically meaningful reduction in PANSS total score versus placebo at Week 5 in the modified intent-to-treat population, with an effect size of 0.37 and a 4.5‑point LS mean improvement (p=0.015). Among trial completers, the effect size was 0.50 with a 6.0‑point LS mean difference (p=0.002), and key secondary endpoints such as CGI‑S and PANSS positive factor also reached significance.
A prespecified cognitive composite endpoint in participants with baseline cognitive impairment showed an effect size of 0.51 (0.44‑point improvement vs placebo; p=0.041) without correlation to PANSS change, suggesting an independent cognitive benefit. ML-007C-MA was generally well tolerated, with no serious or drug‑related severe adverse events, all‑cause discontinuation of 19.9% across active arms, and low rates of GI‑related discontinuations and dose reductions. There were no observed urinary retention, metabolic, hepatic or movement‑related signals, and dosing requires no fasting and only a one‑step titration. MapLight plans an End‑of‑Phase 2 FDA meeting and an additional confirmatory pivotal trial in schizophrenia, while the ongoing VISTA study is evaluating the same 210/3 mg BID dose in Alzheimer’s disease psychosis, with topline results expected in the second half of 2027.
MapLight Therapeutics, Inc. executive Jonathan Gillis, CAO and Interim CFO, reported selling 36,979 shares of Voting Common Stock from July 15–17, 2026 in seven Code S transactions at weighted-average prices ranging from $35.68 to $38.37 per share.
Certain July 15–16 sales are described as mandated “sell to cover” trades to satisfy statutory tax withholding obligations upon restricted stock unit vesting, while the July 17 sales were executed under a Rule 10b5-1 trading plan adopted on December 26, 2025. After one July 17 sale, the table shows 144,240 shares held directly.
MapLight Therapeutics, Inc. reporting person Anatol Kreitzer, Chief Discovery Officer, reported selling 36,284 shares of Voting Common Stock from July 15–17, 2026 at weighted-average prices, with underlying trade prices ranging from $35.68 to $38.21 per share. Sales on July 15–16 covered statutory tax withholding from vesting restricted stock units via mandated “sell to cover” transactions, while July 17 sales were executed pursuant to a Rule 10b5-1 trading plan adopted on December 24, 2025. Following these transactions, Kreitzer directly held 174,906 shares of Voting Common Stock.
MapLight Therapeutics, Inc. CEO and director Christopher A. Kroeger reported sales totaling 147,639 shares of Voting Common Stock between July 15 and 17, 2026. Footnotes state these were mandated sell‑to‑cover transactions to satisfy statutory tax withholding on vested restricted stock units, rather than discretionary sales. After these transactions, he holds 1,246,455 shares directly and 101,190 shares indirectly through the C&M Kroeger Nominee Trust, over which he has voting and dispositive power.
MapLight Therapeutics, Inc. Chief Scientific Officer Lillie James Woodruff reported selling 18,267 shares of Voting Common Stock from July 15–17, 2026, at prices between $35.5338 and $37.925 per share. The disclosure states these mandated sell to cover transactions satisfied statutory tax withholding on vested restricted stock units, leaving her with 224,462 shares held directly.
MapLight Therapeutics, Inc. General Counsel Kristopher Hanson reported sales totaling 16,508 shares of Voting Common Stock between July 15 and 17, 2026. These shares were sold to cover statutory tax withholding obligations arising from vesting restricted stock units, and he now directly holds 145,823 shares.